Related Experiment Videos
Clinical evaluation of a novel beta-lactam antibiotic: pivmecillinam (FL 1039)
Abstract:
Pivmecillinam, a new penicillin-like antibiotic, is a member of the amidinopenicillanic acid group. Its mode of action differs from that of the classical penicillins and it exhibits no cross-resistance with them. Fifty-two gerontopsychiatric patients, median age 81 years, with E. coli, Klebsiella, and Proteus bacteriurias were divided into three comparable groups. In a ten week open clinical trial the patients were treated with pivmecillinam, pivampicillin or the two drugs given alternately in doses reduced in stages. The bacteriuria in all groups cleared almost completely in three days. Pivmecillinam compared favourably with pivampicillin especially at the end of the reduced medication. The alternating treatment seemed to be superior to treatment with either drug administered separately. No development of resistance was observed. No toxic effect on the liver, kidney, or bone marrow was seen in any of the three groups. In the group receiving pivmecillinam alone, no ampicillin-like skin rashes occurred.
Insights
Pivmecillinam effectively treated bacteriuria in elderly patients, showing comparable results to pivampicillin. Alternating treatments were superior, with no observed resistance or toxicity.
Area of Science:
- Pharmacology
- Infectious Diseases
- Geriatrics
Background:
- Pivmecillinam is an amidinopenicillanic acid antibiotic with a distinct mechanism of action and no cross-resistance with traditional penicillins.
- Urinary tract infections (UTIs) are common, particularly in elderly populations, necessitating effective and safe antimicrobial agents.
Purpose of the Study:
- To evaluate the efficacy and safety of pivmecillinam in treating bacteriuria in gerontopsychiatric patients.
- To compare pivmecillinam with pivampicillin and assess the benefits of alternating antibiotic administration.
Main Methods:
- An open clinical trial involving 52 gerontopsychiatric patients (median age 81) with bacteriuria caused by E. coli, Klebsiella, and Proteus.
- Patients were divided into three groups, receiving pivmecillinam, pivampicillin, or alternating doses of both drugs over ten weeks, with gradually reduced dosages.
Main Results:
- Bacteriuria resolved rapidly in all treatment groups, with near-complete clearance within three days.
- Pivmecillinam demonstrated favorable outcomes compared to pivampicillin, particularly during the reduced medication phase.
- Alternating antibiotic therapy appeared more effective than monotherapy, and no antimicrobial resistance or significant toxicity (liver, kidney, bone marrow) was observed.
Conclusions:
- Pivmecillinam is an effective antibiotic for treating bacteriuria in elderly patients, with a favorable safety profile.
- Alternating pivmecillinam and pivampicillin may offer superior therapeutic benefits in managing bacteriuria in this population.
- The study highlights the potential of pivmecillinam as a valuable option for UTI management in geriatrics, with no observed cross-resistance or adverse effects.